As cancer treatment rapidly evolves, Medelis stays on the cutting edge, handling new therapies including immunotherapies, small molecules, vaccines and biologics. We’ve worked with combo regiments, monoclonal antibodies, adoptive T-cell therapy, checkpoint inhibitors and neo-antigen therapy.
We have deep experience managing Phase I through Phase IIIs in the United States and Europe:
We’re experienced with:
Here are the indications we’ve treated over the past 10 years:
Relationships are important to us. Reach out to learn more about how our approach, experience, investigator relationships, bid transparency and flexibility deliver success for our clients.